GlassScriptPhysician profile
Ryan C Garbalosa
NPI 1952539173
$6,754.31
in general payments reported to CMS, 2019-2025
33 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $911 · 2021: $866 · 2022: $1,251 · 2023: $785 · 2024: $1,298 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,196.85 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,101.95 | 2019-2025 | |
| Amgen INC. | $798.20 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $448.08 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $417.46 | 2021-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $411.96 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $237.89 | 2021-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $226.42 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.61 | 2019-2025 | Jardiance |
| Pfizer INC. | $208.75 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $208.69 | 2019-2024 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $153.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.14 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $120.40 | 2022-2024 | |
| Horizon Therapeutics Plc | $101.74 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $80.00 | 2025 | Mi Cancer Seek |
| Atricure, INC. | $73.50 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Kowa Pharmaceuticals America, INC. | $70.31 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $59.43 | 2024 | |
| Daiichi Sankyo INC. | $57.35 | 2024-2025 | Injectafer |
| Amarin Pharma, INC. | $52.71 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $45.37 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $43.64 | 2019 | |
| Abbott Laboratories | $41.51 | 2022-2024 | Mitraclip |
| Inspire Medical Systems, INC. | $37.42 | 2024-2025 | Inspire |
| Philips North America LLC | $36.21 | 2022-2024 | (Ck7) Extended Holter |
| Irhythm Technologies, INC. | $34.93 | 2024 | Zio Xt Patch, Zio Monitor |
| United Therapeutics Corporation | $29.04 | 2024 | Tyvaso |
| Esperion Therapeutics, INC. | $24.00 | 2020 | |
| Boston Scientific Corporation | $21.86 | 2023 | Watchman Flx |
| Vital Connect, INC | $18.16 | 2023 | Vitalpatch Rtm |
| Masimo Corporation | $15.83 | 2023 | Set and Rainbow Set, Patient Safetynet System |
| Preventice Services, LLC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Garbalosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.